CR2Cancer: a database for chromatin regulators in human cancer

Abstract Chromatin regulators (CRs) can dynamically modulate chromatin architecture to epigenetically regulate gene expression in response to intrinsic and extrinsic signalling cues. Somatic alterations or misexpression of CRs might reprogram the epigenomic landscape of chromatin, which in turn lead to a wide range of common diseases, notably cancer. Here, we present CR2Cancer, a comprehensive annotation and visualization database for CRs in human cancer constructed by high throughput data analysis and literature mining. We collected and integrated genomic, transcriptomic, proteomic, clinical and functional information for over 400 CRs across multiple cancer types. We also built diverse types of CR-associated relations, including cancer type dependent (CR-target and miRNA-CR) and independent (protein-protein interaction and drug-target) ones. Furthermore, we manually curated around 6000 items of aberrant molecular alterations and interactions of CRs in cancer development from 5007 publications. CR2Cancer provides a user-friendly web interface to conveniently browse, search and download data of interest. We believe that this database would become a valuable resource for cancer epigenetics investigation and potential clinical application. CR2Cancer is freely available at http://cis.hku.hk/CR2Cancer.

[1]  Jeremy J Jay,et al.  Lollipops in the Clinic: Information Dense Mutation Plots for Precision Medicine , 2016, PloS one.

[2]  Wei Li,et al.  Pediatric cancer epigenome and the influence of folate. , 2015, Epigenomics.

[3]  J. Cortes,et al.  Azacitidine for the treatment of myelodysplastic syndrome , 2009, Expert review of anticancer therapy.

[4]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[5]  Jun S. Liu,et al.  Inference of transcriptional regulation in cancers , 2015, Proceedings of the National Academy of Sciences.

[6]  Zhongming Zhao,et al.  TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes , 2015, Nucleic Acids Res..

[7]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[8]  B. Cairns,et al.  The biology of chromatin remodeling complexes. , 2009, Annual review of biochemistry.

[9]  Sanjay Gupta,et al.  HIstome—a relational knowledgebase of human histone proteins and histone modifying enzymes , 2011, Nucleic Acids Res..

[10]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[11]  Yadong Wang,et al.  miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..

[12]  C. Plass,et al.  Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer , 2013, Nature Reviews Genetics.

[13]  M. Lupien,et al.  A global assessment of cancer genomic alterations in epigenetic mechanisms , 2014, Epigenetics & Chromatin.

[14]  E. Seto,et al.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.

[15]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[16]  Min Zhao,et al.  ONGene: A literature-based database for human oncogenes. , 2017, Journal of genetics and genomics = Yi chuan xue bao.

[17]  P. Munster,et al.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. , 2011, Future oncology.

[18]  Jun'ichi Tsujii,et al.  GENIA corpus - a semantically annotated corpus for bio-textmining , 2003, ISMB.

[19]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[20]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[21]  Graciela Gonzalez,et al.  BANNER: An Executable Survey of Advances in Biomedical Named Entity Recognition , 2007, Pacific Symposium on Biocomputing.

[22]  Mariano J. Alvarez,et al.  Network-based inference of protein activity helps functionalize the genetic landscape of cancer , 2016, Nature Genetics.

[23]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[24]  M. Dawson,et al.  The cancer epigenome: Concepts, challenges, and therapeutic opportunities , 2017, Science.

[25]  Yong Jiang,et al.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.

[26]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[27]  Hanfei Sun,et al.  Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.

[28]  D. Bartel,et al.  Predicting effective microRNA target sites in mammalian mRNAs , 2015, eLife.

[29]  Li Chen,et al.  hmChIP: a database and web server for exploring publicly available human and mouse ChIP-seq and ChIP-chip data , 2011, Bioinform..

[30]  A. Ashworth,et al.  Marked for death: targeting epigenetic changes in cancer , 2017, Nature Reviews Drug Discovery.

[31]  Jing Liu,et al.  CR Cistrome: a ChIP-Seq database for chromatin regulators and histone modification linkages in human and mouse , 2013, Nucleic Acids Res..

[32]  Yue Zhao,et al.  RAID v2.0: an updated resource of RNA-associated interactions across organisms , 2016, Nucleic Acids Res..

[33]  E. Li,et al.  DNA methylation in mammals. , 2014, Cold Spring Harbor perspectives in biology.

[34]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[35]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[36]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[37]  W. Wong,et al.  Modeling gene regulation from paired expression and chromatin accessibility data , 2017, Proceedings of the National Academy of Sciences.

[38]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[39]  T. Mikkelsen,et al.  The NIH Roadmap Epigenomics Mapping Consortium , 2010, Nature Biotechnology.

[40]  Rezvan Ehsani,et al.  EpiFactors: a comprehensive database of human epigenetic factors and complexes , 2015, Database J. Biol. Databases Curation.

[41]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[42]  Tao Liu,et al.  Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse , 2016, Nucleic Acids Res..

[43]  Andrea Califano,et al.  ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information , 2016, Bioinform..

[44]  H. Dweep,et al.  miRWalk2.0: a comprehensive atlas of microRNA-target interactions , 2015, Nature Methods.

[45]  Sharon Y. R. Dent,et al.  Chromatin modifiers and remodellers: regulators of cellular differentiation , 2013, Nature Reviews Genetics.

[46]  Xiaowei Wang,et al.  miRDB: an online resource for microRNA target prediction and functional annotations , 2014, Nucleic Acids Res..

[47]  S. Armstrong,et al.  Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. , 2016, Cancer cell.

[48]  Lijing Yao,et al.  Inferring regulatory element landscapes and transcription factor networks from cancer methylomes , 2015, Genome Biology.

[49]  Andrew E. Teschendorff,et al.  An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer , 2015, Genome Biology.

[50]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[51]  H. Saba.  Decitabine in the treatment of myelodysplastic syndromes , 2007, Therapeutics and clinical risk management.

[52]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[53]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[54]  Jun Zhu,et al.  Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers , 2015, Bioinform..

[55]  Nuria Lopez-Bigas,et al.  The mutational landscape of chromatin regulatory factors across 4,623 tumor samples , 2013, Genome Biology.

[56]  Yu Xue,et al.  WERAM: a database of writers, erasers and readers of histone acetylation and methylation in eukaryotes , 2016, Nucleic Acids Res..

[57]  J. Issa,et al.  Decitabine in the treatment of myelodysplastic syndromes , 2010, Expert review of anticancer therapy.

[58]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[59]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[60]  Tony Kouzarides,et al.  Histone core modifications regulating nucleosome structure and dynamics , 2014, Nature Reviews Molecular Cell Biology.

[61]  Francesca D. Ciccarelli,et al.  NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings , 2015, Nucleic Acids Res..

[62]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[63]  Karolin Luger,et al.  New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? , 2012, Nature Reviews Molecular Cell Biology.